Pozen Inc (POZN) 6.95 $POZN
POZEN wins VIMOVO related patent in the US
M2 - Thu Feb 05, 5:52AM CST
Pharmaceutical company POZEN (NasdaqGS
OZN) reported on Wednesday the receipt of a patent from the US Patent and Trademark Office (USPTO) entitled "Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer" expiring in October 2031.
POZN: 6.95 (+0.15)
POZEN Announces Issuance of VIMOVO(R) Related Patent by the United States Patent and Trademark Office
Business Wire - Wed Feb 04, 3:06PM CST
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced the issuance of a patent by the United States Patent and Trademark Office (USPTO) entitled "Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer" that relates to VIMOVO(R) (naproxen/esomeprazole magnesium) delayed release tablets in patients taking low dose aspirin. The patent expires in October 2031.
HZNP: 16.84 (-0.41), POZN: 6.95 (+0.15)
Nasdaq stocks posting largest percentage decreases
AP - Tue Jan 13, 5:15PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
DISCK: 30.32 (+0.80), ARWR: 6.77 (+0.21), AFMD: 5.70 (-0.25), TFM: 37.14 (+0.07), SRPT: 12.76 (+0.11), DISCB: 31.64 (+0.64), DISCA: 31.45 (+1.11), POZN: 6.95 (+0.15), PEIX: 9.82 (+0.15), GFN: 9.20 (+0.25), HLSS: 16.15 (-0.14), DXPE: 46.57 (+1.42), OBAS: 6.25 (-0.05)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 4:35PM CST
NBIX: 37.22 (+0.27), ROC: 79.20 (+0.33), RUSL: 27.31 (+1.68), RUSS: 11.59 (-0.81), EHIC: 10.48 (-0.01), BURL: 51.91 (-0.56), POZN: 6.95 (+0.15), EXK: 2.48 (+0.08), SEM: 14.32 (+0.11), MCO: 98.22 (+0.01)
Pozen and J&J division cut the cord in migraine drug deal in South America
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 6:44AM CST
POZN: 6.95 (+0.15)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pozen, Inc. - POZN
PR Newswire - Wed Dec 17, 1:24PM CST
Pomerantz LLP is investigating claims on behalf of investors of Pozen, Inc. ("Pozen" or the "Company"
(NasdaqGS: POZN) (CUSIP: 73941U102). Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
POZN: 6.95 (+0.15)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 11:46AM CST
PTRY: 36.72 (+0.05), VIP: 5.37 (+0.51), CCM: 6.84 (-0.10), HGSH: 3.05 (-0.13), CLF: 7.00 (+0.35), ASPX: 65.76 (+2.76), SN: 15.21 (-0.12), NVGN: 2.79 (+0.17), NYNY: 6.33 (+0.06), FVE: 3.74 (+0.18), DRIV: 25.99 (+0.06), SGNL: 3.91 (+2.15), RT: 6.40 (+0.20), SFY: 2.91 (+0.26), VOLC: 17.98 (+0.03), WRES: 1.27 (+0.01), SGNT: 27.75 (-0.41), BBLU: 1.26 (+0.09), POZN: 6.95 (+0.15), XNCR: 15.47 (-0.22)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:13AM CST
CERS: 5.53 (+0.08), FRO: 2.96 (+0.07), KNDI: 12.31 (-0.06), GFI: 4.83 (-0.21), CLF: 7.00 (+0.35), NVGN: 2.79 (+0.17), ASPX: 65.76 (+2.76), DRIV: 25.99 (+0.06), SID: 1.76 (+0.06), HALO: 14.73 (+0.23), VOLC: 17.98 (+0.03), POZN: 6.95 (+0.15), ICLD: 2.87 (+0.11), TASR: 26.96 (-0.42), DGLY: 11.50 (-0.40), SBGL: 10.85 (+0.12)
Pozen receives second CRL for Yosprala, shares drop
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 7:28AM CST
POZN: 6.95 (+0.15)
POZEN's YOSPRALA(TM) Receives Complete Response Letter from The FDA
Business Wire - Wed Dec 17, 5:30AM CST
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that their investigational drug candidates YOSPRALA(TM) 81/40 and 325/40 (aspirin / omeprazole delayed release tablets) have received a second complete response letter (CRL) from the U.S. Food and Drug Administration (FDA). A CRL is issued by the FDA when the review of the file is completed and questions remain that preclude the approval of the new drug application (NDA) in its current form.
POZN: 6.95 (+0.15)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Pozen Inc. Is A Great Opportunity For Investors
Mix Star - at Seeking Alpha - Sat Dec 13, 1:36PM CST
POZN: 6.95 (+0.15)
5 Stocks Insiders Can't Stop Buying: Titan International and More
at The Street - Wed Dec 10, 6:00AM CST
It's important to always be monitoring insider activity but twice as important to make sure the trend of the stock matches up with the insider buying.
DO: 35.21 (+0.36), HCOM: 26.76 (-0.10), POZN: 6.95 (+0.15), GLUU: 5.12 (+0.14), TWI: 9.63 (+0.04)
How To YieldBoost Pozen To 37.5% Using Options
at The Street - Mon Dec 08, 10:32AM CST
Shareholders of Pozen Inc. looking to boost their income beyond the stock's 19.1% annualized dividend yield can sell the June 2015 covered call at the $12 strike and collect the premium based on the 90 cents bid, which annualizes to an additional...
POZN: 6.95 (+0.15)
InsiderInsights.com Daily Round Up 12/3/14: VRX, PSEC, MATR, OCIP
InsiderInsights - at Seeking Alpha - Wed Dec 03, 11:28PM CST
VRX: 167.00 (-0.50), HCOM: 26.76 (-0.10), MATR: 7.07 (-0.12), ARI: 16.70 (-0.07), RENT: 58.90 (+0.39), LLY: 70.56 (+0.03), SPB: 94.05 (+0.80), GOOG: 549.01 (+6.08), DXPE: 46.57 (+1.42), K: 63.20 (-0.10), DO: 35.21 (+0.36), OCIP: 16.27 (-0.46), NOW: 77.55 (+1.60), COF: 78.88 (-0.41), DYN: 28.39 (+0.01), TWTR: 48.50 (+0.55), POZN: 6.95 (+0.15), DATA: 99.90 (+1.40), EL: 82.49 (+1.58), PSEC: 8.67 (+0.07)
POZEN (POZN) Is Weak On High Volume Today
at The Street - Wed Dec 03, 9:06AM CST
Trade-Ideas LLC identified POZEN (POZN) as a weak on high relative volume candidate
POZN: 6.95 (+0.15)
POZEN wins VIMOVO related patent in the US
M2 - Thu Feb 05, 5:52AM CST
Pharmaceutical company POZEN (NasdaqGS
OZN) reported on Wednesday the receipt of a patent from the US Patent and Trademark Office (USPTO) entitled "Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer" expiring in October 2031. POZN: 6.95 (+0.15)
POZEN Announces Issuance of VIMOVO(R) Related Patent by the United States Patent and Trademark Office
Business Wire - Wed Feb 04, 3:06PM CST
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced the issuance of a patent by the United States Patent and Trademark Office (USPTO) entitled "Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer" that relates to VIMOVO(R) (naproxen/esomeprazole magnesium) delayed release tablets in patients taking low dose aspirin. The patent expires in October 2031.
HZNP: 16.84 (-0.41), POZN: 6.95 (+0.15)
Nasdaq stocks posting largest percentage decreases
AP - Tue Jan 13, 5:15PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
DISCK: 30.32 (+0.80), ARWR: 6.77 (+0.21), AFMD: 5.70 (-0.25), TFM: 37.14 (+0.07), SRPT: 12.76 (+0.11), DISCB: 31.64 (+0.64), DISCA: 31.45 (+1.11), POZN: 6.95 (+0.15), PEIX: 9.82 (+0.15), GFN: 9.20 (+0.25), HLSS: 16.15 (-0.14), DXPE: 46.57 (+1.42), OBAS: 6.25 (-0.05)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 4:35PM CST
NBIX: 37.22 (+0.27), ROC: 79.20 (+0.33), RUSL: 27.31 (+1.68), RUSS: 11.59 (-0.81), EHIC: 10.48 (-0.01), BURL: 51.91 (-0.56), POZN: 6.95 (+0.15), EXK: 2.48 (+0.08), SEM: 14.32 (+0.11), MCO: 98.22 (+0.01)
Pozen and J&J division cut the cord in migraine drug deal in South America
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 6:44AM CST
POZN: 6.95 (+0.15)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pozen, Inc. - POZN
PR Newswire - Wed Dec 17, 1:24PM CST
Pomerantz LLP is investigating claims on behalf of investors of Pozen, Inc. ("Pozen" or the "Company"
(NasdaqGS: POZN) (CUSIP: 73941U102). Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. POZN: 6.95 (+0.15)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 11:46AM CST
PTRY: 36.72 (+0.05), VIP: 5.37 (+0.51), CCM: 6.84 (-0.10), HGSH: 3.05 (-0.13), CLF: 7.00 (+0.35), ASPX: 65.76 (+2.76), SN: 15.21 (-0.12), NVGN: 2.79 (+0.17), NYNY: 6.33 (+0.06), FVE: 3.74 (+0.18), DRIV: 25.99 (+0.06), SGNL: 3.91 (+2.15), RT: 6.40 (+0.20), SFY: 2.91 (+0.26), VOLC: 17.98 (+0.03), WRES: 1.27 (+0.01), SGNT: 27.75 (-0.41), BBLU: 1.26 (+0.09), POZN: 6.95 (+0.15), XNCR: 15.47 (-0.22)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:13AM CST
CERS: 5.53 (+0.08), FRO: 2.96 (+0.07), KNDI: 12.31 (-0.06), GFI: 4.83 (-0.21), CLF: 7.00 (+0.35), NVGN: 2.79 (+0.17), ASPX: 65.76 (+2.76), DRIV: 25.99 (+0.06), SID: 1.76 (+0.06), HALO: 14.73 (+0.23), VOLC: 17.98 (+0.03), POZN: 6.95 (+0.15), ICLD: 2.87 (+0.11), TASR: 26.96 (-0.42), DGLY: 11.50 (-0.40), SBGL: 10.85 (+0.12)
Pozen receives second CRL for Yosprala, shares drop
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 7:28AM CST
POZN: 6.95 (+0.15)
POZEN's YOSPRALA(TM) Receives Complete Response Letter from The FDA
Business Wire - Wed Dec 17, 5:30AM CST
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that their investigational drug candidates YOSPRALA(TM) 81/40 and 325/40 (aspirin / omeprazole delayed release tablets) have received a second complete response letter (CRL) from the U.S. Food and Drug Administration (FDA). A CRL is issued by the FDA when the review of the file is completed and questions remain that preclude the approval of the new drug application (NDA) in its current form.
POZN: 6.95 (+0.15)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Pozen Inc. Is A Great Opportunity For Investors
Mix Star - at Seeking Alpha - Sat Dec 13, 1:36PM CST
POZN: 6.95 (+0.15)
5 Stocks Insiders Can't Stop Buying: Titan International and More
at The Street - Wed Dec 10, 6:00AM CST
It's important to always be monitoring insider activity but twice as important to make sure the trend of the stock matches up with the insider buying.
DO: 35.21 (+0.36), HCOM: 26.76 (-0.10), POZN: 6.95 (+0.15), GLUU: 5.12 (+0.14), TWI: 9.63 (+0.04)
How To YieldBoost Pozen To 37.5% Using Options
at The Street - Mon Dec 08, 10:32AM CST
Shareholders of Pozen Inc. looking to boost their income beyond the stock's 19.1% annualized dividend yield can sell the June 2015 covered call at the $12 strike and collect the premium based on the 90 cents bid, which annualizes to an additional...
POZN: 6.95 (+0.15)
InsiderInsights.com Daily Round Up 12/3/14: VRX, PSEC, MATR, OCIP
InsiderInsights - at Seeking Alpha - Wed Dec 03, 11:28PM CST
VRX: 167.00 (-0.50), HCOM: 26.76 (-0.10), MATR: 7.07 (-0.12), ARI: 16.70 (-0.07), RENT: 58.90 (+0.39), LLY: 70.56 (+0.03), SPB: 94.05 (+0.80), GOOG: 549.01 (+6.08), DXPE: 46.57 (+1.42), K: 63.20 (-0.10), DO: 35.21 (+0.36), OCIP: 16.27 (-0.46), NOW: 77.55 (+1.60), COF: 78.88 (-0.41), DYN: 28.39 (+0.01), TWTR: 48.50 (+0.55), POZN: 6.95 (+0.15), DATA: 99.90 (+1.40), EL: 82.49 (+1.58), PSEC: 8.67 (+0.07)
POZEN (POZN) Is Weak On High Volume Today
at The Street - Wed Dec 03, 9:06AM CST
Trade-Ideas LLC identified POZEN (POZN) as a weak on high relative volume candidate
POZN: 6.95 (+0.15)
